List of Contents

In Vivo CRO Market Size, Share, and Trends 2024 to 2034

The global in vivo CRO market size was USD 4.62 billion in 2023, calculated at USD 4.99 billion in 2024 and is expected to be worth around USD 10.89 billion by 2034. The market is slated to expand at 8.11% CAGR from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 4783
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on In Vivo CRO Market 

5.1. COVID-19 Landscape: In Vivo CRO Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global In Vivo CRO Market, By Model Type

8.1. In Vivo CRO Market, by Model Type, 2024-2033

8.1.1. Rodent Based

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Non-Rodent Based

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global In Vivo CRO Market, By Modality

9.1. In Vivo CRO Market, by Modality, 2024-2033

9.1.1. Small Molecules

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Large Molecules

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global In Vivo CRO Market, By Indication 

10.1. In Vivo CRO Market, by Indication, 2024-2033

10.1.1. Oncology

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. CNS Conditions

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Diabetes

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Obesity

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Pain Management

10.1.5.1. Market Revenue and Forecast (2021-2033)

10.1.6. Autoimmune/Inflammation Conditions

10.1.6.1. Market Revenue and Forecast (2021-2033)

10.1.7. Others

10.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global In Vivo CRO Market, By GLP Type 

11.1. In Vivo CRO Market, by GLP Type, 2024-2033

11.1.1. GLP Toxicology

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Non-GLP

11.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global In Vivo CRO Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.1.2. Market Revenue and Forecast, by Modality (2021-2033)

12.1.3. Market Revenue and Forecast, by Indication (2021-2033)

12.1.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Modality (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Indication (2021-2033)

12.1.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Modality (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Indication (2021-2033)

12.1.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.2.2. Market Revenue and Forecast, by Modality (2021-2033)

12.2.3. Market Revenue and Forecast, by Indication (2021-2033)

12.2.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Modality (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Indication (2021-2033)

12.2.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Modality (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Indication (2021-2033)

12.2.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Modality (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Indication (2021-2033)

12.2.7.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Modality (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Indication (2021-2033)

12.2.8.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.3.2. Market Revenue and Forecast, by Modality (2021-2033)

12.3.3. Market Revenue and Forecast, by Indication (2021-2033)

12.3.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Modality (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Indication (2021-2033)

12.3.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Modality (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Indication (2021-2033)

12.3.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Modality (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Indication (2021-2033)

12.3.7.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Modality (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Indication (2021-2033)

12.3.8.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.4.2. Market Revenue and Forecast, by Modality (2021-2033)

12.4.3. Market Revenue and Forecast, by Indication (2021-2033)

12.4.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Modality (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Indication (2021-2033)

12.4.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Modality (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Indication (2021-2033)

12.4.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Modality (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Indication (2021-2033)

12.4.7.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Modality (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Indication (2021-2033)

12.4.8.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.5.2. Market Revenue and Forecast, by Modality (2021-2033)

12.5.3. Market Revenue and Forecast, by Indication (2021-2033)

12.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Modality (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Indication (2021-2033)

12.5.5.4. Market Revenue and Forecast, by GLP Type (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Model Type (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Modality (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Indication (2021-2033)

12.5.6.4. Market Revenue and Forecast, by GLP Type (2021-2033)

Chapter 13. Company Profiles

13.1. IQVIA Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Crown Bioscience

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Taconic Biosciences, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. PsychoGenics Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Evotec

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Janvier Labs

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Biocytogen Boston Corp

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. GemPharmatech

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Charles River Laboratories

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Icon Plc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client